Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Futibatinib plus Pembrolizumab in Advanced or Metastatic Urothelial Carcinoma
2024-513760-26-00Phase 2Completed
- Sponsor
- Taiho Oncology
- Start
- Jul 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label trial of futibatinib and pembrolizumab in transitional cell carcinoma (TCC) (3 arms), sponsored by Taiho Oncology. Primary endpoint: Objective response rate (ORR). Started Jul 2024; status: completed.
02
Drugs
futibatinibpembrolizumab
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on 2024-513760-26-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513760-26-00.